Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHRM.L Regulatory News (PHRM)

  • There is currently no data for PHRM

Operational Update

3 Jul 2015 07:00

RNS Number : 0770S
Phorm Corporation Limited
03 July 2015
Β 

3 July 2015

Β 

Phorm Corporation Limited

("Phorm"Β orΒ theΒ "Company)

Β 

Operational Update

Β 

Phorm (AIM: PHRM), a leading internet personalisation technology company, announces an unaudited operational and financial update showing further strong growth in the group's revenues and key performance indicators ("KPIs").

Β 

RUSSIA

Β 

Key Performance Indicator

2014 Q3

2014 Q4

2015 Q1

2015 Q2

Average of daily unique users (m)

12.5

23.9

31.5

35.5

Total advertising requests (m)

16,625.3

25,437.3

40,343.5

83,018.9

Total advertisements served (m)

126.9

295.5

342.0

393.3

Total revenues (m RUB)

2.0

9.8

15.7

29.0

Β 

Β 

The three core components of the Company's business model are users, inventory (advertising requests) and advertising campaigns (advertisements served). These components are put in place sequentially in order to generate revenue.

Β 

In terms of users in Russia, the Company is delighted to announce that the average daily unique user numbers has grown from 12.5 million in Q3 2014 to 35.5 million in Q2 2015. These figures serve to demonstrate the scale of the opportunity available to the Company.

Β 

The number of advertising requests to which the Company has access in Russia has also increased significantly. The number of requests has more than doubled from 40.3 billion in Q1 2015 to 83.1 billion Q2 2015. Phorm now has publishing deals in place with some of the largest players in the market and the Company expects this to continue to grow over the coming months.

Β 

The most important component of the Company's business model is the advertising campaigns. The growth in both advertisements served and revenues provides evidence of the increasing adoption of Phorm's product in the market. Unaudited revenue derived from Russia has almost doubled, from RUB15.7 million (approximately US$0.3 million) in Q1 2015 to RUB29.0 million (approximately US$0.5 million) in Q2 2015. The growth in revenue is based on demonstrating the performance of the platform to the advertisers through a series of paid for test campaigns. Phorm is now working with six of the top tier global agencies in Russia.

Β 

Phorm is also delighted to announce that, following these results, five of the agencies have agreed to begin integrating Phorm's platform into their trading desks, which is expected to significantly increase the number of campaigns to which Phorm has access. In addition, two of these agencies have already started integration training. The Company is particularly pleased with this development as it provides rapid access to large numbers of campaigns without having to increase the cost base of our Russian operations.

Β 

United States of America ("US")

Β 

Key Performance Indicator

2015 Q2

Average of daily unique users (m)

42.4

Total advertising requests (m)

361,331.8

Total advertisements served (m)

65.9

Β 

Β 

The Company announced on 21 April 2015 that is had started commercial operations in the US and has been very pleased with the initial reaction it has received in the market.

Β 

In terms of users, Phorm has been able to build an audience comparatively quickly and, on average, now has access to 42.4 million daily unique users.

Β 

The Company has placed significant focus on its ability to integrate with third parties, as it is a route to generating significant commercial scale rapidly. The initial results of this strategy can be seen by the number of advertising requests to which the Company has access. In Q2 2015, Phorm had access to 361.3 billion advertising requests, which is four times more than in Russia and achieved in significantly less time.

Β 

At this stage, the Company is serving both paid and free test campaigns. There are currently eight campaigns running and Phorm is delighted with the way these initial campaigns are performing and is confident that the majority, if not all, of the free test campaigns will convert to paid-for campaigns in the near future. The pipeline of potential opportunities in the US currently stands at over US$0.5 million and the Company expects this to grow rapidly.

Β 

As in Russia, the Company will be pursuing a strategy of integrating its technology with the trading desks of the major agencies to quickly access large numbers of campaigns.

Β 

China

Β 

In China, as the Company announced on 21 April 2015, the focus has been on developing a partnership with a large local player. A number of these discussions are progressing and further announcements will be made as and when appropriate.

Β 

Β 

-Ends-

Β 

For further information please contact:

Phorm Corporation Limited

Andy Croxson (analysts and investors) +44 20 3397 6001

Β 

UK Investors

Mirabaud Securities LLP (Broker) +44 20 7321 2508

Jason Woollard

Peter Krens

Β 

Strand Hanson Limited (Nominated Adviser) +44 20 7409 3494

James Harris

Matthew Chandler

James Dance

Β 

US Investors

Lippert/Heilshorn and Associates (Investor Relations) +1 212 838 3777

John Heilshorn

Β 

Β 

About Phorm

Β 

Phorm is a global personalisation technology company that makes content and advertising more relevant to the consumer. Phorm's innovative platform preserves user privacy and delivers a more interesting online experience.

Β 

Phorm's industry leading technology enables its ISP partners to offer a new type of online advertising platform and a free consumer internet content feature, ensuring more relevant advertisements and personalised content for opted-in users.

Β 

Phorm's advertising platform revolutionises current standards of online privacy, fully protecting the identity of consumers. Phorm's solution is completely opt-in. Only those users consenting to the service are profiled and only ever on an anonymous basis.

Β 

Phorm's partners include leading ISPs, Publishers, Advertising Networks and Advertisers.

Β 

Phorm, under a predecessor holding company, was admitted to trading on the AIM market of the London Stock Exchange in 2004.

Β 

For more information, please visit: www.phorm.com

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
MSCLLLLBEDFZBBQ
Date   Source Headline
5th Jan 20107:00 amRNSTransfer of shares
17th Dec 200911:51 amRNSPurchase of Shares and Total Voting Rights
4th Nov 20092:18 pmRNSNotification of major interest in shares
2nd Nov 200912:42 pmRNSResult of AGM
6th Oct 20092:07 pmRNSNotice of AGM
2nd Oct 20097:00 amRNSNotification of major interest in shares
21st Sep 20097:00 amRNSInterim results
14th Sep 20098:57 amRNSNotification of Results
5th Aug 20097:00 amRNSTransfer of Shares
8th Jul 20098:27 amRNSOperational Update
6th Jul 20099:22 amRNSStatement on UK operations
30th Jun 20097:13 amRNSAnnual Accounts
19th Jun 200911:06 amRNSTotal Voting Rights
18th Jun 20097:00 amRNSFinal Results
10th Jun 20097:00 amRNSPlacing to raise ?15 million
3rd Jun 200911:00 amRNSPhorm announces Webwise Discover
21st May 20097:00 amRNSKorean Market Trial
27th Apr 200910:31 amRNSStatement re Apology from "New Media Age" Magazine
14th Apr 20096:23 pmRNSPhorm Statement re EU Commission
9th Apr 20093:57 pmRNSAIM Block Admission
30th Mar 20097:00 amRNSKorean Market Trial
26th Mar 20097:03 amRNSGrant of Options
19th Mar 20091:31 pmRNSGrant of Options
18th Mar 20097:00 amRNSChange of Broker
13th Mar 20095:03 pmRNSShare Issue - Replacement
13th Mar 20092:46 pmRNSShare Issue
11th Mar 20099:49 amRNSAnnouncement of Appointments
4th Mar 20093:18 pmRNSCity Events Wire
17th Dec 20085:52 pmRNSManagement Appointments
15th Dec 20087:00 amRNSBT Trial Update
1st Dec 20087:00 amRNSPhorm Announces Board Changes
5th Nov 20087:46 amRNSDisclosure of Share Sale
22nd Oct 20085:14 pmRNSGrant of options
14th Oct 200810:15 amRNSCancellation of admission of shares
30th Sep 20087:00 amRNSInterim Results
29th Sep 20087:00 amRNSCommencement of BT Trial
22nd Sep 200811:15 amRNSResponse to Statement by BERR
4th Sep 20087:00 amRNSPhorm Update
18th Aug 20087:00 amRNSAppointment of Independent Bo
24th Jun 20087:00 amRNSTransfer of Shares
14th May 20084:45 pmRNSExercise of Options
14th May 200812:55 pmRNSAnnual Report and Accounts
10th Apr 20087:01 amRNSFinal Results
4th Apr 20084:23 pmRNSNotification of Holding
4th Apr 20084:16 pmRNSNotification Of Shareholding
4th Apr 200812:11 pmRNSNotification Of Shareholding
19th Mar 20087:01 amRNSIssue of Equity
13th Mar 200811:32 amRNSResult of Stockholder Meeting
11th Mar 20087:02 amRNSRe Share Price Movement
28th Feb 20085:50 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.